Company Encyclopedia
View More
name
Compass Pathways
CMPS.US
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
1.946 T
CMPS.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Compass Pathways to Join Evercore and Piper Sandler Healthcare Conferences

    Compass Pathways plc will participate in fireside chats at the 8th Annual Evercore Healthcare Conference on December 2, 2025, in Coral Gables, FL, and at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, in New York, NY. Live audio webcasts will be available on the Compass website. This information was originally published by Compass Pathways via Business Wire.

    Reuters·
    US
    CMPS
    +11.59%
    Reuters·
    US
    CMPS
    +11.59%

    The "Big 4" Psychedelic Compound-Based Drug Discovery Stocks Fell 14% Last Week - Here's Why

    The "BIG 4" psychedelic compound-based drug discovery stocks fell an average of 13.9% in the week ending November 7, following a 9.6% rise in October. Key players include GH Research PLC, COMPASS Pathways, Mind Medicine Inc., and Atai Beckley N.V., each experiencing declines due to various catalysts such as valuation concerns, investor caution, and sector-wide weakness. The economic impact of mental health disorders is significant, with global productivity losses estimated at $1 trillion annually, highlighting the potential market for psychedelic therapies.

    Talkmarkets·
    US
    GHRS
    +6.75%
    US
    CMPS
    +11.59%
    Talkmarkets·
    US
    GHRS
    +6.75%
    US
    CMPS
    +11.59%

    Buy Rating for COMPASS Pathways: Accelerated Clinical Development and Strategic Position in Mental Health Sector

    Maxim Group analyst Michael Okunewitch has maintained a Buy rating on COMPASS Pathways with a price target of $12.00, citing the company's accelerated clinical development in the mental health sector. Key factors include proactive studies on psilocybin therapy, regulatory insights, and institutional support for psychedelic therapies. Additionally, COMPASS's application for the Commissioner’s National Priority Voucher could expedite market entry. H.C. Wainwright also reiterated a Buy rating with a $40.00 target, reflecting confidence in the company's upcoming data releases and strong cash position.

    Tip Ranks·
    US
    CMPS
    +11.59%
    Tip Ranks·
    US
    CMPS
    +11.59%

    RBC Capital Sticks to Their Buy Rating for COMPASS Pathways (CMPS)

    According to TipRanks, Timashev is a 5-star analyst with an average return of 28.0% and a 60.34% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Alkermes, Insmed, and IDEAYA Biosciences. COMPASS Pathways has an analyst consensus of Strong Buy, with a price target consensus of $19.67.

    Tip Ranks·
    US
    CMPS
    +11.59%
    Tip Ranks·
    US
    CMPS
    +11.59%

    Compass Pathways to Participate in Stifel 2025 Healthcare Conference

    Compass Pathways plc will participate in the Stifel 2025 Healthcare Conference in New York on November 11, 2025, at 10:40 am ET. A live audio webcast will be available on the company's website. This announcement is for informational purposes only and should not be considered financial or legal advice.

    Reuters·
    US
    CMPS
    +11.59%
    Reuters·
    US
    CMPS
    +11.59%
    © 2025 Longbridge｜Disclaimer